Overview

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Status:
Not yet recruiting
Trial end date:
2024-06-26
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
ViiV Healthcare